Satsuma Pharmaceuticals (STSA) Financials

$1.10

$0.00 (0.00%)

As on 09-Jun-2023 09:30EDT

Market cap

$37 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.4

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-13	Dec-12	Dec-11	Dec-10
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Operating Expenses	54.44	59.22	51.17	48.33	28.88	7.52
Operating Profit (EBIT)	-66.17	-70.95	-51.17	-48.33	-28.88	-7.52
Other Income	--	--	--	--	--	--
Profit before Tax	-64.83	-70.06	-51.17	-47.56	-28.18	-7.35
Provision for Tax	-1.50	-0.89	0.01	-0.24	-0.14	--
Profit after Tax (Net Income)	-63.33	-69.16	-51.18	-47.32	-28.03	-7.35
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-31.41	--	-51.17	-47.56	-28.18	-7.35

Liabilities ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-13	Dec-12	Dec-11	Dec-10
Shareholder's Funds	37.65	-211.79	101.34	-90.56	-43.00	-12.13
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.99	2.05	2.55	1.05	2.97	16.55
Current Liabilities	5.83	8.12	8.49	8.05	7.97	1.97
Total Liabilities	49.31	54.94	109.83	81.03	126.28	6.38

Assets ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-13	Dec-12	Dec-11	Dec-10
Non-Current Assets	0.10	0.13	9.98	7.25	11.53	0.98
Current Assets	43.38	54.81	99.85	73.79	114.74	5.40
Total Assets	49.31	54.94	109.83	-81.47	-32.06	6.38
Total Debt*	0.12	0.14	1.08	3.03	4.93	4.97
Net Current Assets	37.54	46.69	91.36	65.74	106.77	3.44

Cashflow ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-13	Dec-12	Dec-11	Dec-10
Cash From Operating Activities	--	-51.52	-43.00	-42.33	-29.64	-6.98
Cash Flow from Investing Activities	--	--	-50.78	58.00	-95.88	-0.40
Cash from Financing Activities	--	8.74	73.28	-2.10	143.06	10.93
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-13	Dec-12	Dec-11	Dec-10
Adjusted EPS ($)	-1.97	-2.16	-1.76	-2.78	-4.67	--
Cash EPS ($)	--	-2.14	-1.75	-2.77	-4.65	--
Adjusted Book Value ($)	--	--	3.49	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-1.61	-1.48	-2.49	-4.94	--
Free Cash Flow per Share ($)	--	-1.62	-1.55	-2.79	-5.03	--

Profitability Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-13	Dec-12	Dec-11	Dec-10
ROCE (%)	--	126.63	-687.51	75.35	123.94	117.49
ROE (%)	-119.47	125.24	-949.85	70.86	101.70	83.65
ROA (%)	-84.69	-83.95	-53.63	-45.66	-42.27	-175.64
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-13	Dec-12	Dec-11	Dec-10
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	-17.75	-38.66	-5.87	-67.33	-298.03	-40.70
Net Profit Growth (%)	-12.74	-35.14	-8.14	-68.81	-281.62	-42.03
EPS Growth (%)	-9.09	-0.22	0.37	0.40	--	--
Book Value Growth (%)	-58.03	--	--	--	--	--

Valuation Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-13	Dec-12	Dec-11	Dec-10
Price / Earnings	--	-0.42	-2.55	-1.66	-4.21	--
Price / Book Value	0.42	-0.14	1.29	-0.87	-2.75	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	0.57	0.40	-0.76	-0.28	-0.55	--
Close Price ($)	0.70	0.90	4.50	4.61	19.68	--
High Price ($)	8.08	8.08	7.48	36.11	21.60	--
Low Price ($)	0.59	0.59	4.06	3.50	8.61	--
Market Cap ($ Cr)	36.80	--	--	--	--	--

Solvency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-13	Dec-12	Dec-11	Dec-10
Debt to Equity	--	0.00	0.01	-0.03	-0.11	-0.41
Short term debt to equity ratio	0.00	0.00	0.01	-0.02	-0.05	-0.01
Current Ratio	7.44	6.75	11.76	9.17	14.40	2.75
Quick Ratio	7.44	--	--	--	--	--
Interest Coverage	-63.77	-5,457.46	-313.90	-138.08	-59.92	-80.62

Operating Efficiency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-13	Dec-12	Dec-11	Dec-10
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.